Metabolic syndrome: Historical perspectives

American Journal of the Medical Sciences

Volumn 330, Issue 6, 2005, Pages 264-268

  Leslie, Bruce R ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adipose tissue; History of medicine; Insulin resistance; Metabolic syndrome X

Indexed keywords

FAT; INSULIN;

ADIPOSE TISSUE; ATHEROSCLEROSIS; BODY FAT DISTRIBUTION; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE COURSE; GLUCOSE INTOLERANCE; HEART DISEASE; HISTORY OF MEDICINE; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; MOLECULAR EVOLUTION; OBESITY; RECOGNITION; SKINFOLD THICKNESS; THROMBOSIS;

EID: 29244440864     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200512000-00002     Document Type: Conference Paper

References (49)

1. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-89.
2. Lakka HM, Laaksonen DE, Lakka TA, et al . The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
3. Alexander CM, Landsman PB, Teutsch SM, et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-14.
4. Meigs JB. Invited commentary: Insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000;152:908-11.
5. Ferrannini E, Haffner SM, Mitchell BD, et al. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991;34:416-22.
6. Chen J, Muntner P, Hamm L, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004;140:167-74.
7. Vuorinen-Markkola H, Yki-Jarvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab 1994;78:25-9.
8. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005;293:455-62.
9. Medina J, Fernandez-Salazar LI, Garcia-Buey L, et al. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004;27:2057-66.
10. Grundy S. Cholesterol gallstones: a fellow traveler with metabolic syndrome? Am J Clin Nutr 2004;80:1-2.
11. Yaffe K, Kanaya A, Lindquist K, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004;292:2237-42.
12. Flint A. A practical treatise on the diagnosis, pathology, and treatment of diseases of the heart. Philadelphia: Blanchard and Lea; 1859. p. 93.
13. Osler W. The Lumleian lectures on angina pectoris. Lancet 1910;i:839-44.
14. White PD. Heart disease. 3rd ed. New York: The Macmillan Company; 1944. p. 536.
15. Levine SA. Clinical heart disease. 5th ed. Philadelphia: W.B. Saunders Company; 1958. p. 95.
16. Vague J. La differenciation sexuelle. Facteur determinant des formes de l'obesite. Presse Med 1947;55:339-40.
17. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956;4:20-34.
18. Albrink MJ, Meigs JW. Interrelationship between skinfold thickness, serum lipids and blood sugar in normal men. Am J Clin Nutr 1964;15:255-61.
19. Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982;54:254-60.
20. Krotkiewski M, Bjorntorp P, Sjostrom L, et al. Impact of obesity on metabolism in men and women: Importance of regional adipose tissue distribution. J Clin Invest 1983;72:1150-62.
21. Bjorntorp P. Metabolic implications of body fat distribution. Diabetes Care 1991;14:1132-43.
22. Fujioka S, Matsuzawa Y, Tokunaga K, et al. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987;36:54-9.
23. Montague CT, Prins JB, Sanders L, et al. Depot- and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. Diabetes 1997;46:342-47.
24. Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004;12:180-86.
25. Skurk T, Hauner H. Obestiy and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004;28:1357-64.
26. Albright F, Burnett CH, Smith PH, et al. Pseudo-hypoparathyroidism: an example of 'Seabright-Bantam Syndrome.' Report of three cases. Endocrinology 1942;30:922-32.
27. Himsworth HP. Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1936;i:127-130.
28. Himsworth HP, Kerr RB. Insulin-sensitive and insulin-insensitive types of diabetes mellitus. Clin Sci 1939;4:119-52.
29. Yalow RS, Berson SA. Plasma insulin concentrations in nondiabetic and early diabetic subjects: determinations by a new sensitive immuno-assay technic. Diabetes 1960;9:254-60.
30. Welborn TA, Breckenridge A, Dollery CT, et al. Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet 1966;i:1336-37.
31. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-23.
32. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
33. Modan M, Halkin H, Almog S, et al. Hyperinsulinemia: a link between hypertension obesity and glucose intolerance. J Clin Invest 1985;75:809-17.
34. Hanefeld M, Leonhardt W. Das metabolische Syndrom. Dt Gesundh-Wesen 1981;36:545-51.
35. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
36. Dean JD, Jones CJH, Hutchison SJ, et al. Hyperinsulinaemia and microvascular angina ("syndrome X"). Lancet 1991;337:456-7.
37. Kaplan NM. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989;149:1514-20.
38. DeFronzo RA, Ferrannini E. Insulin resistance: a multi-faceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
39. Zimmet PZ . Kelly West lecture 1991. Challenges in diabetes epidemiology - from West to the rest. Diabetes Care 1992;15:232-52.
40. Hjermann I. The metabolic cardiovascular syndrome: syndrome X, Reaven's syndrome, insulin resistance syndrome, atherothrombogenic syndrome. J Cardiovasc Pharmacol 1992;20(suppl 8):S5-S10.
41. Zimmet P, Boyko EJ, Collier GR, et al. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann N Y Acad Sci 1999;892:25-44.
42. Hill JO. What to do about the metabolic syndrome? Arch Intern Med 2003;163:395-7.
43. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004;33:283-303.
44. World Health Organization. The metabolic syndrome. http://whqlibdoc.who. int/hq/1999/WHO_NCD_NCS_99,2.pdf
45. National Cholesterol Education Program. Third report of the national cholesterol education program on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Circulation 2002;106:3143-421.
46. Americal College of Endocrinology. ACE position statement on the insulin resistance syndrome. Endocr Pract 2003;9:240-52.
47. Grundy SM, Brewer HB, Cleeman JI, et al. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-38.
48. American Association of Clinical Endocrinologists. New ICD-9-CM code for dysmetabolic syndrome X. http://www.aace.com/members/socio/syndromex.php
49. Breitstein J. The making of a new disease. Science is beginning to understand the role of insulin resistance. Now it's industry's turn to draw the blueprints for the biggest market yet. Pharmaceutical Executive http://www.pharmexec.com/ pharmexec/article/articleDetail.jsp?id=80917.